Literature DB >> 15743749

Multitarget FISH analysis in the diagnosis of lung cancer.

Lukas Bubendorf1, Phaedra Müller, Ladina Joos, Bruno Grilli, Sandrine Vogel, Michelle Herzog, Audrey Barascud, Georg Feichter, Peter Dalquen, Michael Tamm.   

Abstract

The aim of the present study was to explore the diagnostic usefulness of the multitarget fluorescence in situ hybridization (FISH) test, LAVysion (Vysis, Downers Grove, IL), for the detection of lung cancer cells in cytologic specimens. Specimens from bronchial washings, bronchial brushings, and transbronchial fine-needle aspirates (TBNAs) from 100 patients with suspected lung cancer and from a control group of 71 patients with nonneoplastic lung disorders were analyzed. FISH positivity was defined as more than 5 cells with gains of at least 2 chromosomes or gene loci. FISH significantly improved the sensitivity of bronchial brushings from 49% to 73%. The specificities of FISH and cytologic examination were 87% and 100%, respectively. In contrast, FISH provided no additional diagnostic information in TBNAs and bronchial washings. There was no increased prevalence of genetic changes in contralateral bronchial washings from patients with lung cancer compared with the control group. The quantity of previous smoking had no effect on the prevalence of chromosomal changes.

Entities:  

Mesh:

Year:  2005        PMID: 15743749     DOI: 10.1309/F5AD-JUWV-D2WF-L8J5

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  9 in total

1.  A potential probe set of fluorescence in situ hybridization for detection of lung cancer in bronchial brushing specimens.

Authors:  Yi-Zhen Liu; Zhen Wang; Li-Li Fang; Lu Li; Jian Cao; Xin Xu; Ya-Ling Han; Yan Cai; Liang-Xu Wang; Ming-Rong Wang
Journal:  J Cancer Res Clin Oncol       Date:  2012-04-27       Impact factor: 4.553

2.  [Cytology in the internet].

Authors:  K Glatz; L Bubendorf; D Glatz
Journal:  Pathologe       Date:  2007-09       Impact factor: 1.011

3.  Analysis of Chromosome 3, 7 and 8 Centromeric Regions in Bronchial Lavage Specimens by FISH.

Authors:  Sezen Atasoy; Salih Serdar Erturan; Nail Yılmaz; Dilhan Kuru; Ayşe Çırakoğlu; Şükriye Yılmaz; Ayhan Deviren
Journal:  Turk Thorac J       Date:  2016-10-01

Review 4.  Update on biomarkers for the detection of lung cancer.

Authors:  Eloisa Jantus-Lewintre; Marta Usó; Elena Sanmartín; Carlos Camps
Journal:  Lung Cancer (Auckl)       Date:  2012-06-11

5.  The relationship between the presence of chromosomal instability and prognosis of squamous cell carcinoma of the lung: fluorescence in situ hybridization analysis of paraffin-embedded tissue from 47 Korean patients.

Authors:  Jung-Wan Yoo; Kwang Won Seo; Se Jin Jang; Yeon-Mock Oh; Tae Sun Shim; Woo Sung Kim; Dong-Soon Lee; Sang-Do Lee; Chang-Min Choi
Journal:  J Korean Med Sci       Date:  2010-05-24       Impact factor: 2.153

Review 6.  Molecular biology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Serge Patrick Nana-Sinkam; Charles A Powell
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

7.  [Fluorescence in situ hybridization. A new diagnostic dimension in cytology].

Authors:  S Savic; L Bubendorf
Journal:  Pathologe       Date:  2007-09       Impact factor: 0.973

8.  High frequency of genetic alterations in non-small cell lung cancer detected by multi-target fluorescence in situ hybridization.

Authors:  Ji Un Kang; Sun Hoe Koo; Kye Chul Kwon; Jong Woo Park; So Youn Shin; Jin Man Kim; Sung Su Jung
Journal:  J Korean Med Sci       Date:  2007-09       Impact factor: 2.153

9.  Recurrent genomic gains in preinvasive lesions as a biomarker of risk for lung cancer.

Authors:  Pierre P Massion; Yong Zou; Hasmet Uner; Porntip Kiatsimkul; Holly J Wolf; Anna E Baron; Tim Byers; Steinn Jonsson; Stephen Lam; Fred R Hirsch; York E Miller; Wilbur A Franklin; Marileila Varella-Garcia
Journal:  PLoS One       Date:  2009-06-09       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.